Skip to main content

Grafa News and Videos — Page 912

Grafa Headlines

Latest

Grafa

Larimar Therapeutics submits first BLA module for nomlabofusp in Friedreich’s ataxia

Larimar Therapeutics (NASDAQ:LRMR) announced the submission of the first module of a rolling Biologics License Application to the U.S. Food and Drug Administration seeking accelerated approval of nomlabofusp for the treatment of Friedreich’s ataxia.

Read more: Larimar Therapeutics submits first BLA module for nomlabofusp in Friedreich’s ataxia

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift